Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Personalised melanoma vaccine cuts risk of recurrence

Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...

Research project to produce fish-free omega-3

SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...

Biodegradable smart patch can detect and treat blood clots

Researchers have developed a biodegradable smart patch that detects pressure changes and releases...

Content from other channels on our network

MathWorks certified to provide guidance for AI‍-‍assisted engineering

CSIRO suggests ways Australia can grow battery manufacturing sector

NSW opens expressions of interest for Bradfield enterprise precinct

UQ researchers develop faster membrane technology

Rockwell Automation introduces SecureOT capabilities for OEMs

Winning healthcare equipment tenders: why having the best product is no longer enough

Optimising connectivity: Peninsula University Hospital

When pressure narrows the choices healthcare leaders can see

When AI Wastes More Than a Patient's Time

Aged care's Single Assessment System has "undermined public confidence", ombudsman finds

Six on the shelf: diverse new food products in November

tna's food packaging solution wins gold at the Good Design Awards 2026

NSW Wine Recovery Program now open for applications

AIP to host its final State of Industry Webinar for 2026

Contamination detection solutions for the food manufacturing industry